Physician profile
Howard Silverman
NPI 1861412496
$1,592.83
in general payments reported to CMS, 2019-2025
24 companies · $229 in 2025
The $229 reported for 2025 was more than what 77% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $290 · 2021: $189 · 2022: $156 · 2023: $302 · 2024: $258 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $386.47 | 2019-2024 | Jornay Pm |
| Corium, LLC | $170.53 | 2021-2025 | Azstarys |
| Pfizer INC. | $143.67 | 2019-2025 | |
| Cranial Technologies, INC | $114.43 | 2020-2024 | Doc Band |
| Supernus Pharmaceuticals, INC. | $106.18 | 2021-2023 | Qelbree |
| Kaleo, INC. | $82.32 | 2021-2023 | Auvi-Q |
| Neos Therapeutics, Lp | $79.10 | 2019-2023 | Cotempla Xr-Odt |
| Sanofi Pasteur INC. | $74.57 | 2019-2025 | |
| Tris Pharma INC | $63.26 | 2020-2023 | Dyanavel Xr |
| Bayer Healthcare Pharmaceuticals INC. | $46.67 | 2023-2024 | |
| Glaxosmithkline, LLC. | $44.39 | 2022-2025 | Bexsero, Penmenvy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.99 | 2019-2021 | |
| Teleflex LLC | $35.53 | 2024 | Deflux |
| Sobi, INC | $28.20 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $27.00 | 2025 | Neffy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.05 | 2024 | |
| Collegium Pharmaceutical, INC. | $21.73 | 2025 | Jornay Pm |
| Seqirus USA INC | $17.59 | 2021 | |
| Merck Sharp & Dohme LLC | $16.11 | 2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Biofire Diagnostics, LLC | $15.75 | 2019 | |
| Sarepta Therapeutics, INC. | $14.79 | 2019 | |
| Dermira, INC. | $13.54 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.85 | 2019 | |
| Biogen, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.